Crescent Biopharma
CBIO
85 hedge funds and large institutions have $668M invested in Crescent Biopharma in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 10 closing their positions.
25% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $1.23M
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 84 → 85 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 1.09% → 1.08% (-0.01%)
11% less capital invested
Capital invested by funds: $747M → $668M (-$79.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$22.1M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.88M |
| 3 |
Man Group
London,
United Kingdom
|
+$5.37M |
| 4 |
JG
Jefferies Group
New York
|
+$2.58M |
| 5 |
Axa
Paris,
France
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$16.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.12M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$4.7M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.03M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.55M |
CBIO Hedge Fund Activity: Q3 2018 in Review
85 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2018, worth a combined $668M — down 11% from $747M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CBIO positions and 10 closed out — a net gain of 1 holder — while 31 added to existing stakes and 25 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $22.1M. The largest seller was Polar Capital, exiting entirely with an estimated $16.9M sold.
- 85 institutional investors held Crescent Biopharma (CBIO) as of Q3 2018, up from 84 in Q2 2018.
- Funds reported $668M of Crescent Biopharma stock for Q3 2018, down 11% quarter-over-quarter.
- 11 funds opened new Crescent Biopharma positions in Q3 2018 and 10 closed out, a net change of +1 holder.
- The largest Crescent Biopharma buyer in Q3 2018 was OppenheimerFunds, an estimated $22.1M added.
- The largest Crescent Biopharma seller in Q3 2018 was Polar Capital, an estimated $16.9M sold.
Based on aggregated 13F filings for Q3 2018.